Novartis milestones be proud ! Management take a bow !

Funny this is the same statment after Bribes in the;

United States
Korea
China
Russian
Japan
France
Italy
Turkey
Baltics
etc etc etc etc etc etc

"“Novartis is committed to the highest standards of ethical business conduct and regulatory compliance in all aspects of its work and takes any allegation of misconduct extremely seriously.”"

REALLY? lots of 'isolated rouge incidents' ....globally no less

 

yep. this is going down in the record books. for now.

 

this is true for most industrial concerns where revs run in the multi-billions.
the corporate-controlled economy is corrupt to the core.

 

Unbelievable

 

Desperate times for Joe Jimenez, now he wants to sell Roche stock, hit with embarrassing lackluster launches and getting slammed by investors. With Joe, it's "all about the numbers" and if you don't hit those numbers, many good employees have fallen and lost their jobs. So, when does someone pull the plug on this over rated ketchup guy?

 

novartis is nothing but politics.

 

what makes you think the company's plug has not already been pulled?

 

Colombian minister proposes ending Novartis patent
By Anand Chandrasekhar

4-28-2016

The Colombian Health Minister Alejandro Gaviria has announced that he will start proceedings to divest Novartis of its patent on the cancer drug Glivec Imatinib. The Swiss government was accused of lobbying against such a move.
On April 26, Gaviria revealed plans to approach the Colombian patent office and ask it to strip the Novartis patent on the grounds of public interest. This could lead the patent office to grant a compulsory license to allow the generic production of Glivec Imatinib at affordable prices by domestic firms.

In November 2014, a group of Colombian NGOs had asked the health ministry to declare access to Glivec a matter of public interest.

“It is a very courageous decision by the minister given the pressure from his own commerce ministry, Novartis, the US, Switzerland, and the pharma industry as a whole,” Patrick Durisch of the Swiss NGO Berne Declaration told swissinfo.ch.

The move would save Colombia around CHF12 million ($12.4 million) a year, he added.

The process of preparing a resolution to submit to the Colombian patent office will take a couple of weeks, and it will be a few months before the office announces its decision.

Tug of war
Four years ago, Colombia’s patent office denied Novartis’ patent for Glivec Imatinib. But the Swiss pharma giant took the issue to court and received a favourable decision in 2012. The patent prohibited the production of generic versions of the drug, which were 70% cheaper than the original.

The Colombian health minister then tried to negotiate with Novartis to bring the price of the drug down to 140 Mexican Peso (CHF7.8) per milligram from its current price of 300 Mexican Peso. But Novartis refused to budge on the price of Glivec Imatinib.

In 2014, Colombian NGOs requested that the health minister declare removing the Glivec Imatinib patent a matter of public interest. This would set into motion the process of stripping Novartis of its patent and allow cheap generic versions to be produced by domestic firms.

The Swiss government actively lobbied against this move in 2015, prompting accusations of siding with Novartis to the detriment of poor Colombian

A Novartis spokesperson told swissinfo.ch that the company was not against the practice of issuing compulsory licenses in exceptional circumstances such as a public health crisis but was against the use of such a clause to force price negotiation.

"In the case of Glivec in Colombia, a DPI [Declaration of Public Interest] is inappropriate as there is no shortage of Glivec or evidence of other access issues, the price is already subject to government controls and there no monopoly with multiple generics already on the market."

 

With Joe J, it's all about the numbers. If you didn't hit your numbers, he had no problem destroying your career. So, he's not hitting his numbers and the company is in a death spiral, will he get the axe? Wake up NVS board!

 

The World is saved ! fof the record, cornflakes reported direct to ketchup boy & yet nothing changd &/or got worse....just sayn

Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
May 03, 2016, 08:15:00 AM EDT By Dow Jones Business News

Novartis AG's chief ethics and compliance officer, Eric Cornut, is retiring from his role, according to a company spokesman.

Mr. Cornut—who reported directly to Chief Executive Joe Jimenez—had been in the post since August 2014, when Novartis created the position to raise the compliance function to the highest levels of the company. He will stay on as a special adviser on government affairs to Mr. Jimenez, the spokesman said.

Shannon Klinger, previously general counsel for Novartis's generic-drug division, Sandoz, took up the ethics-and-compliance role on Sunday, though Mr. Cornut, 58, won't step down from his duties until June 1 to assist with the handover, the spokesman added. Unlike Mr. Cornut, Ms. Klinger will also head litigation for Novartis in her new role.

Novartis has said it disagrees with the government's characterization of its behavior and disputes the allegations.

Last year, Novartis paid $390 million to the Justice Department to settle allegations that the company induced specialty pharmacies to boost prescriptions for Novartis drugs by paying kickbacks in the form of rebates.

In settling, Novartis admitted to a series of facts relating to its relationship with specialty pharmacies, but neither admitted nor denied wrongdoing. Mr. Jimenez has said the rebates were designed to induce specialty pharmacies to ensure that patients completed a course of medicine.

Mr. Cornut spent his nearly two years in post leading the development of an integrity and compliance program "that is further strengthening Novartis's culture, reporting and commercial relationships around the world," according to the spokesman.

Mr. Cornut's career at the drugmaker began in 1989 at Ciba-Geigy, which merged with Sandoz in 1996 to form Novartis. Prior to his current role, he was chief commercial officer, overseeing affairs such as drug pricing. Before then, he led Novartis's European pharmaceuticals business.

 

Does anyone at Novartis have ethics?

 

She is great when it comes to protecting the company and deflecting....just another brilliant move ....Novartis will continue to NOT have an effective compliance program.

 

Our "leaders" are just a bunch of headless chickens running this company to its inevitable collapse.

 

YES!!!

 

https://www.statnews.com/pharmalot/2016/05/11/obama-novartis-patents/

#crookedpharma

 

Imagine that. Protect drug profits for a drug already generic in india & the USA
even if it means continues war with drug cartels

http://www.huffingtonpost.com/entry/colombia-gleevec_us_5733d4ece4b077d4d6f224ee

 

Trump will put an end to these power plays by the pharma lobby when he becomes President.

 

http://www.huffingtonpost.com/noam-chomsky/american-power-under-challenge-who-rules-the-world_b_9866204.html

We cannot gain a realistic understanding of who rules the world while ignoring the “masters of mankind,” as Adam Smith called them: in his day, the merchants and manufacturers of England; in ours, multinational conglomerates, huge financial institutions, retail empires, and the like. Still following Smith, it is also wise to attend to the “vile maxim” to which the “masters of mankind” are dedicated: “All for ourselves and nothing for other people” -- a doctrine known otherwise as bitter and incessant class war, often one-sided, much to the detriment of the people of the home country and the world.

In the contemporary global order, the institutions of the masters hold enormous power, not only in the international arena but also within their home states, on which they rely to protect their power and to provide economic support by a wide variety of means. When we consider the role of the masters of mankind, we turn to such state policy priorities of the moment as the Trans-Pacific Partnership, one of the investor-rights agreements mislabeled “free-trade agreements” in propaganda and commentary. They are negotiated in secret, apart from the hundreds of corporate lawyers and lobbyists writing the crucial details. The intention is to have them adopted in good Stalinist style with “fast track” procedures designed to block discussion and allow only the choice of yes or no (hence yes). The designers regularly do quite well, not surprisingly. People are incidental, with the consequences one might anticipate.

 

http://colombiareports.com/swiss-novartis-private-interests-threatening-us-peace-funds-colombia/

Are Swiss Novartis’ private interests threatening US peace funds for Colombia?
written by Adriaan Alsema May 13, 2016

Colombia’s embassy in the United States is concerned that efforts to lower the price of a life-saving cancer drug threatens Washington DC’s promised funds for peace in Colombia, according to a leaked memo published by the Huffington Post.

The embassy’s business attache in Washington DC sent the memo to Foreign Minister Maria Angela Holguin, also a member of the negotiation team seeking a peace deal with the FARC, the country’s oldest and largest rebel group that is currently in talks to end more than half a century of violence.

The warning came in April, days after Colombia’s health minister said he may issue a decree that would allow a generic company to make a lower-cost version of the Gleevec leukemia treatment and save the South American country $12 million annually.

According to business attache Andres Florez, ambassador Juan Carlos Pinzon has already been called in for a meeting with the US Trade Representative (USTR) Michael Froman over the plans.

Additionally, industry representatives and lobbyists have already pressured Colombia to maintain Novartis’ price.